SILO NASDAQ
Silo Pharma, Inc.
1W: -16.6%
1M: -41.6%
3M: -76.5%
YTD: +335.0%
1Y: +113.0%
3Y: -15.6%
5Y: +689.2%
$1.46
-0.04 (-2.80%)
Weekly Expected Move ±8.0%
$1
$1
$1
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-04-07
Earliest Filing
2026-04-02
Latest Filing
partner: 7
acquirer: 2
licensee: 1
Counterparties (Filed by SILO)
10 relationshipsCompanies named in SILO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Many Ads Inc. | — | acquirer | Silo Pharma, Inc. acquired software assets and domain names from Many Ads Inc. in exchange for 2,100,000 shares of commo | 2026-04-02 | View |
| MAVS Holdings LLC | — | acquirer | Asset purchase agreement for software and domain names | 2025-07-29 | View |
| University of Maryland, Baltimore | — | partner | Silo Pharma, Inc. entered into a termination and license agreement with UMB regarding CNS-homing peptides intellectual p | 2025-07-10 | View |
| Columbia University | — | partner | Exclusive license agreement for patents and technical information regarding stress-induced affective disorders. | 2024-07-08 | View |
| University of Maryland, Baltimore | — | partner | Entered into a Fourth Amendment to Master License Agreement regarding diligence milestones. | 2024-06-27 | View |
| University of Maryland, Baltimore | — | partner | Third Amendment to Master License Agreement regarding diligence milestones | 2023-11-14 | View |
| Columbia University | — | partner | Sponsored research agreement for licensing assets related to Alzheimer's disease and Stress Induced Anxiety. | 2022-10-18 | View |
| Columbia University | — | partner | Sponsored research agreement for Alzheimer's disease asset licensing and development | 2021-10-27 | View |
| AIkido Pharma Inc. | — | partner | Patent License Agreement amendment involving delivery of Series M Convertible Preferred Stock | 2021-04-16 | View |
| AIkido Pharma, Inc. | — | licensee | Silo Pharma granted an exclusive worldwide sublicense for neuroinflammatory disease treatment in cancer patients. | 2021-04-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-08-19 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-08-17 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-07-13 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-06-18 | Other Events; Exhibits | View | |
| 2026-06-03 | Bylaws Amendment; Other Events; Exhibits | View | |
| 2026-06-01 | Other Events | View | |
| 2026-04-02 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-02-23 | Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-29 | Notice of Delisting or Transfer | View | |
| 2025-10-24 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-10-01 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-08-05 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-29 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-07-10 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-07-03 | Notice of Delisting or Transfer | View | |
| 2025-05-16 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-03-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-02 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR